Optimization of energy substrate utilization and delivery, promotion of cellular renewal through the activation of autophagic pathways, attenuation of sympathetic tone, and improvement in vascular function are some of the potential mechanisms for SGLT2 inhibitors’ observed benefits in CKD. This evidence concerns the gene SLC5A2 and chronic kidney disease.